The Zero Declaration is a cry for global action against TB. Read and sign on to the Declaration!

An essay seeking to elucidate the reasons for the anemic response to drug-resistant tuberculosis by examining the recent history of tuberculosis policy.

The FDA will aim to complete its review within six months of the NDA submission. The NDA was submitted June 29.

A research to investigate for the first time the effect of vitamin D on the immune responses of patients receiving treatment for an infectious disease.

While many European countries are progressing towards TB elimination, the target of less than 1 TB case/1,000,000 population is still far from being achieved everywhere.

If approved, bedaquiline could be one of the first drugs with a new mechanism of action for TB in more than 40 years and one of the first ever to be specifically indicated for MDR-TB.

An estimated one-third of TB infections in the Southern African region are linked to mining activities. 

Nearly half of tuberculosis patients studied in eight countries are resistant to at least one second-line drug and some 7% of cases are extensively drug-resistant.

The use of newer drugs, a greater number of effective drugs, and a longer treatment regimen may be associated with improved survival of patients with multidrug resistant tuberculosis.

How the U.S.’s intellectual property demands for the Trans-Pacific Partnership Agreement threaten access to medicines.